NO931580D0 - Anvendelse av antistoffer mot tnf eller fragmenter avledet derav og xantinderivater for kombinasjonsterapi og preparater derfor - Google Patents

Anvendelse av antistoffer mot tnf eller fragmenter avledet derav og xantinderivater for kombinasjonsterapi og preparater derfor

Info

Publication number
NO931580D0
NO931580D0 NO931580A NO931580A NO931580D0 NO 931580 D0 NO931580 D0 NO 931580D0 NO 931580 A NO931580 A NO 931580A NO 931580 A NO931580 A NO 931580A NO 931580 D0 NO931580 D0 NO 931580D0
Authority
NO
Norway
Prior art keywords
tnf
antibody
xanthine
range
xanthine derivative
Prior art date
Application number
NO931580A
Other languages
English (en)
Norwegian (no)
Inventor
Hiristo Anagnostopulos
Ulrich Gebert
Heinz Hanel
Michael Limbert
Mark William Bodmer
Gerald Anthony Higgs
Original Assignee
Celltech Ltd
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Ltd, Hoechst Ag filed Critical Celltech Ltd
Publication of NO931580D0 publication Critical patent/NO931580D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO931580A 1990-11-01 1993-04-30 Anvendelse av antistoffer mot tnf eller fragmenter avledet derav og xantinderivater for kombinasjonsterapi og preparater derfor NO931580D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909023783A GB9023783D0 (en) 1990-11-01 1990-11-01 Pharmaceutical product
PCT/GB1991/001907 WO1992007585A1 (fr) 1990-11-01 1991-10-30 Utilisation d'anticorps contre le tnf, ou de fragments derives de ceux-ci, ainsi que de derives xanthiques pour la therapie d'association, et compositions associees

Publications (1)

Publication Number Publication Date
NO931580D0 true NO931580D0 (no) 1993-04-30

Family

ID=10684716

Family Applications (1)

Application Number Title Priority Date Filing Date
NO931580A NO931580D0 (no) 1990-11-01 1993-04-30 Anvendelse av antistoffer mot tnf eller fragmenter avledet derav og xantinderivater for kombinasjonsterapi og preparater derfor

Country Status (15)

Country Link
EP (1) EP0564461B1 (fr)
JP (1) JP3468515B2 (fr)
KR (1) KR930701970A (fr)
AT (1) ATE146971T1 (fr)
AU (1) AU653180B2 (fr)
CA (1) CA2094154A1 (fr)
DE (1) DE69123984T2 (fr)
DK (1) DK0564461T3 (fr)
ES (1) ES2096662T3 (fr)
GB (1) GB9023783D0 (fr)
GR (1) GR3022210T3 (fr)
HU (1) HUT70267A (fr)
NO (1) NO931580D0 (fr)
WO (1) WO1992007585A1 (fr)
ZA (1) ZA918712B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
AU5152293A (en) * 1992-10-08 1994-05-09 Kennedy Institute Of Rheumatology, The Treatment of autoimmune and inflammatory disorders
US6770279B1 (en) 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
RU2139092C1 (ru) 1993-06-03 1999-10-10 Терапьютик Антибодиз Инк. Фрагменты антител в терапии
AU1090795A (en) * 1993-11-12 1995-05-29 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
DE4411660A1 (de) * 1994-04-05 1995-10-12 Hoechst Ag Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung
AU5696198A (en) * 1996-12-06 1998-06-29 Amgen, Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
SI0942740T1 (en) * 1996-12-06 2003-12-31 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
US6294350B1 (en) * 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6395273B1 (en) * 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease

Also Published As

Publication number Publication date
EP0564461A1 (fr) 1993-10-13
AU653180B2 (en) 1994-09-22
EP0564461B1 (fr) 1997-01-02
HU9301093D0 (en) 1993-07-28
DE69123984D1 (de) 1997-02-13
DE69123984T2 (de) 1997-05-22
JP3468515B2 (ja) 2003-11-17
CA2094154A1 (fr) 1992-05-02
DK0564461T3 (da) 1997-01-20
JPH06502629A (ja) 1994-03-24
HUT70267A (en) 1995-09-28
WO1992007585A1 (fr) 1992-05-14
ES2096662T3 (es) 1997-03-16
GB9023783D0 (en) 1990-12-12
KR930701970A (ko) 1993-09-08
GR3022210T3 (en) 1997-04-30
ZA918712B (en) 1992-09-30
ATE146971T1 (de) 1997-01-15
AU8758391A (en) 1992-05-26

Similar Documents

Publication Publication Date Title
NO931580D0 (no) Anvendelse av antistoffer mot tnf eller fragmenter avledet derav og xantinderivater for kombinasjonsterapi og preparater derfor
DE69724451D1 (de) Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
NO20053862L (no) Aktiv immunisering for a danne antistoffer mot loselig A-beta
WO1997044461A3 (fr) Fragments de liaison a l'antigene detectant specifiquement des cellules cancereuses, nucleotides codant lesdits fragments, et leur utilisation pour la prophylaxie et le depistage de cancers
EP1238986A3 (fr) Utilisation d'antagonistes du facteur de croissance cellulaire VEGF
NO913211L (no) Nytt monoklonalt antistoff mot nytt antigen knyttet til menneske-tumorer.
IL103981A0 (en) Pharmaceutical compositions for treatment of multiple sclerosis
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
NO914541L (no) Fremgangsmaate ved fremstilling av tumor-nekrose-faktor-muteiner
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
ATE120372T1 (de) Antikörper für die antilymphozyten- antikörpertherapie.
ATE349468T1 (de) Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung
EP0369816A3 (fr) Anticorps monoclonaux spécifiques pour la mucine polymorphe épithéliale humaine
WO1996020950A3 (fr) Compositions et therapies pour le traitement de la polyarthrite rhumatoide
NZ328940A (en) Methods and use t cell epitopes of lol p v ryegrass pollen antigens
NO961423D0 (no) Oligopeptider avledet fra C-reaktive proteinfragmenter
RU2519196C2 (ru) Лекарственное средство для лечения патологического синдрома и способ лечения рассеянного склероза
Roszkiewicz et al. Tocilizumab w leczeniu młodzieńczego idiopatycznego zapalenia stawów o początku uogólnionym–doświadczenia własne
EP0321094A3 (fr) Traitement des inhibiteurs de facteur VIII
RU2446821C2 (ru) Лекарственное средство для лечения инфекционных заболеваний, сопровождающихся нейротоксическими нарушениями, и способ лечения инфекционных заболеваний, сопровождающихся нейротоксическими нарушениями
GB2233559A (en) Antibodies for use in antilymphocyte antibody therapy
ITO et al. ISOLATION and PURIFICATION of EARLY PREGNANCY FACTOR using large number of PREGNANCY SWINE SERUM
CA2255540A1 (fr) Fragments de liaison a l'antigene detectant specifiquement des cellules cancereuses, nucleotides codant lesdits fragments, et leur utilisation pour la prophylaxie et le depistage de cancers
ES2158776A1 (es) Procedimiento para la obtencion de gammaglobulinas de origen animal y aplicaciones correspondientes.